Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
October 05 2022 - 3:05PM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced it will host a webcast and conference call on Thursday,
October 6, 2022, at 8:00 a.m. (ET) to report top-line results from
Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate
injection, United States Pharmacopeia) for intravitreal
administration in patients with proliferative vitreoretinopathy
(PVR), a rare, sight-threatening ocular disease with no approved
therapy.
The dial-in numbers are (844) 200-6205 for domestic callers and
(646) 904-5544 for international callers. The access code is
005042. A live audio webcast of the conference call also will be
accessible from the “Investors & Media” section of Aldeyra's
website at ir.aldeyra.com.
After the live webcast, the event will remain archived on
Aldeyra’s website for 90 days.
About Aldeyra
Aldeyra is a clinical-stage biotechnology company developing
innovative therapies designed to treat immune-mediated diseases.
Our approach is to discover pharmaceuticals that modulate
immunological systems, instead of directly inhibiting or activating
single protein targets, with the goal of optimizing multiple
pathways at once while minimizing toxicity. Two of our lead product
candidates, reproxalap and ADX-629, target pre-cytokine,
systems-based mediators of inflammation known as RASP (reactive
aldehyde species). Reproxalap is in late-stage clinical trials in
patients with dry eye disease and allergic conjunctivitis. ADX-629,
an orally administered RASP modulator, is in Phase 2 clinical
testing for the treatment of systemic immune-mediated diseases. Our
pipeline also includes ADX-2191 (methotrexate injection, United
States Pharmacopeia) for intravitreal administration, in
development for the prevention of proliferative vitreoretinopathy
and the treatment of retinitis pigmentosa and primary vitreoretinal
lymphoma. For more information, visit https://www.aldeyra.com and
follow us on LinkedIn, Facebook, and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221005005669/en/
Investor & Media: Scott Solomon Sharon Merrill
Associates, Inc. Tel: (857) 383-2409 ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
